China 2014 Regulatory Outlook: Expect Greater Enforcement As CFDA Rolls Out New Regs
This article was originally published in The Pink Sheet Daily
Executive Summary
The year 2014 could see China FDA implement a series of rules, including revisions to the Drug Registration Regulation and the Medical Device Administration Regulation, which could significantly impact the pharmaceutical and medical device industries.
You may also be interested in...
FDA Inspection Growth In China Stymied By Visa Issues
The agency is waiting for approval to locate 10 new drug inspectors in China.
U.S. FDA Launches First Overseas Office in Beijing
U.S. HHS Secretary Michael Leavitt and U.S. FDA Commissioner Andrew von Eschenbach officially opened the first overseas FDA office Nov. 19 in Beijing in a continuing effort to improve foreign product safety, while the agency faces criticism from the U.S. Congress
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues.